

Important changes to Octapharma Products distributed by CBS: Introduction of a New Reconstitution Device for Octaplex, Fibryga and Wilate powder vials.

Date: March 31, 2025

Dear Health Care Professional,

Octapharma Canada is pleased to announce a new, easy-to-use reconstitution device for our factor concentrate products—**Octaplex®**, **Fibryga®**, and **Wilate®**. This device, Nextaro®, simplifies preparation, significantly reduces the number of steps, and helps minimize handling errors. We expect these updates to boost efficiency, reduce wastage, and ease training requirements.

Enclosed are the updated Product Monographs for your reference.

Why are we changing the reconstitution device?



Nextaro® was specifically developed by Octapharma R&D to reduce user errors and streamline the process of reconstituting the powder with the provided Water For Injection (WFI).

The device is manufactured in Switzerland and meet all current environmental standards.

Key Benefits for Hospitals

1. Faster Bedside Administration

- Nextaro® supports quick, bedside reconstitution, potentially eliminating the need for blood bank preparation.
- This can save up to 30 minutes in transit and setup time—crucial for improving patient outcomes in critical care scenarios.

2. Error-Free, Consistent Reconstitution

- The device is specifically designed to reduce the likelihood of reconstitution errors and speeds up staff training.
- Fewer steps mean easier onboarding for new team members and more consistent results.

Octapharma Canada Inc.
1000-25 King Street West

Phone: +1 (416) 531-9951
Email: info.canada@octapharma.com

3. **Reduced Wastage and Fewer Technical Complaints**

- By simplifying the reconstitution process, Nextaro® lowers the risk of handling errors.
- This reduction in errors can decrease the need for product returns and complaint submissions.

Key Benefits for Patients

1. **Simplified Home Infusions**

- Fewer steps mean shorter preparation times and a lower risk of errors, especially for patients or caregivers at home.

2. **Less Training Required**

- Onboarding new patients or transitioning to prophylaxis treatment at home becomes faster and easier.

Timeline for Product Updates

This transition will occur in three phases during 2025 to ensure a smooth adjustment at your facility. Each product's rollout will include training resources and support:

- **Fibryga®**: Currently reconstituted with Octajet. Will change to Nextaro® in May 2025.
- **Octaplex®**: Currently reconstituted with Mix2vial. Will change to Nextaro® in June 2025.
- **Wilate®**: Currently reconstituted with Mix2vial. Will change to Nextaro® in September 2025.

Important: Existing kits with Mix2vial or Octajet are still valid and safe to use until they expire. Please dispense these first, and do not return them to CBS. Octapharma Canada will continue to provide support for these devices during the transition.

Resources and Support

Octapharma Canada is committed to a seamless transition and will provide the following:

1. **Comprehensive Resources via a dedicated microsite**

- A dedicated [microsite](#) will host training materials, reconstitution guides, downloadable FAQs.

2. **Training Sessions**

- Our product specialists will work with your transfusion safety team to arrange in-person or virtual sessions.
- To request additional training, visit the [microsite](#) and click "Book Training Session."

3. **Demo Kits**

Octapharma Canada Inc.
1000-25 King Street West

Phone: +1 (416) 531-9951
Email: info.canada@octapharma.com

- Product-specific demo kits will be available before your scheduled training session.
- To request additional kits, visit the [microsite](#) and click “Request Demo Kits.” (Quantities are limited.)

4. Additional Contact Details

<u>For product and hospital queries:</u> Vivian Tran Key Account Manager, Coagulation Therapies vivian.tran@octapharma.com +1 416 700 5953	<u>For medical information:</u> Alison Dyer Medical Affairs Associate Alison.dyer@octapharma.com +1 416 670 1595
<u>For supply chain related queries:</u> Ricardo Segovia Senior Supply Chain Specialist Ricardo.segovia@octapharma.com +1 647 327 3184	<u>Key team contacts:</u> <ul style="list-style-type: none"> • For medical queries related to any of our products: medinfo.canada@octapharma.com • To Report an adverse event or side effect adr.canada@octapharma.com • To report a product technical complaint: quality.canada@octapharma.com

Thank you for your continued partnership and cooperation in delivering the best possible care to your patients.

Sincerely,

Alison Dyer,
Medical Affairs Associate
On behalf of Octapharma Canada

References:

1. Product Monograph Fibryga
2. Product Monograph Octaplex
3. Product Monograph Wilate